Target symptoms for fluvoxamine in old age depression

Area of Science:

• Geriatric Psychiatry
• Clinical Pharmacology

Background:

• Geriatric depression presents unique challenges, differing biochemically and clinically from younger-onset depression.
• Elderly patients often exhibit irritability, anxiety, and cognitive issues, with poorer treatment responses.
• Distinct clinical manifestations and biochemical underpinnings suggest age-specific depression mechanisms.

Purpose of the Study:

• To evaluate the efficacy of fluvoxamine in treating major depression or dysthymia in elderly patients.
• To assess the impact of fluvoxamine on depressive symptoms, cognitive function, and daily activities in geriatric depression.

Main Methods:

• A study involving 50 geriatric patients (mean age 66.65) diagnosed with depression (DSM-IV criteria).
• Patients received daily fluvoxamine (100 mg) for 3 months.
• Assessments included Geriatric Depression Scale (GDS), Hamilton Depression Rating Scale (HDRS), Mini-Mental State Examination (MMSE), Cambridge Neuropsychological Test Battery (CAMCOG), and Functional Rating Scale for Senile Dementia (FRSSD).

Main Results:

• Statistically significant improvements were observed in Geriatric Depression Scale (GDS) and Functional Rating Scale for Senile Dementia (FRSSD) scores.
• While mean scores for MMSE and CAMCOG showed changes, they were not statistically significant.
• All patients experienced residual symptoms post-treatment.

Conclusions:

• Fluvoxamine effectively improved depressive thought content (GDS) and daily functioning (FRSSD) in elderly patients.
• Patients with co-occurring cognitive impairment showed a greater treatment response.
• Severely depressed patients exhibited a more pronounced response but also more residual symptoms.